drugset / Press release
NEW DATA SHOWS STELARA® (USTEKINUMAB) MAINTAINED CLINICAL RESPONSE AND REMISSION AFTER TWO YEARS OF TREATMENT IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
2017-02-17 · Janssen Research & Development, LLC · original jnj.com ↗
NEWS RELEASE NEW DATA SHOWS STELARA® (USTEKINUMAB) MAINTAINED CLINICAL RESPONSE AND REMISSION AFTER TWO YEARS OF TREATMENT IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE 2/17/2017 1
The release as fetched from its publisher. jnj.com ↗